Nancy Olivieri

Source: Wikipedia, the free encyclopedia.

Nancy Fern Olivieri (born 1954) is a prominent

pharmaceutical company Apotex about the drug deferiprone.[1]

Early life

Olivieri was born to the Hamilton, Ontario, Doctor Fernando Olivieri and Victoria Olivieri.[2] Her paternal grandfather had immigrated to Hamilton from Italy in 1909.[2] Olivieri received a Bachelor of Science from the University of Toronto and an MD from McMaster University in 1978.[3] She has also pursued training in Internal Medicine and Hematology at McMaster, University of Toronto, and Harvard University.[3]

Deferiprone controversy

Starting in 1989, Olivieri was part of a group evaluating the use of a drug,

hepatic fibrosis.[4][5]

Olivieri's scientific findings, which sparked the controversy, have been challenged on the basis of data from clinical trials conducted by Apotex.[6][7][8]

Deferiprone is approved for use in over 50 countries, but not in Canada.[9] It was approved in the US in 2011 under the FDA's accelerated approval program.[10]

An investigation commissioned by the Canadian Association of University Teachers (CAUT) revealed that one of Olivieri's critics, Gideon Koren, had anonymously sent disparaging letters about Olivieri to the media and colleagues. Koren initially denied responsibility, but substantial DNA evidence tied him to the letters, and he was reprimanded.[11]

Olivieri has advocated greater academic freedom and called for less control of research by pharmaceutical companies.[12] This situation was publicised extensively and was investigated by the Canadian Association of University Teachers.[11]

Awards and honours

Olivieri was awarded the 2009 AAAS Award for Scientific Freedom and Responsibility for her "indefatigable determination that patient safety and research integrity come before institutional and commercial interests and for her courage in defending these principles in the face of severe consequences."[13]

Olivieri is the 2023 recipient of the John Maddox Prize in recognition of her “determination to act with integrity…in the face of extreme pressure from the company producing it, ultimately at great personal cost” in the Deferiprone controversy.[14] The Maddox Prize is awarded by the UK-based Sense about Science charity in partnership with Nature (journal).

See also

References

  1. ^
    PMID 14872065
    .
  2. ^ a b "'Uncle Red': Barton Street's kid doctor". thespec.com. August 21, 2011.
  3. ^ a b "Nancy Olivieri - Institute of Medical Science - University of Toronto". ims.utoronto.ca.
  4. .
  5. ^ Hadskis, Michael (2007). "The Regulation of Human Biomedical research in Canada". In Downie, Jocelyn (ed.). Canadian Health Law and Policy (textbook). et al. (Third ed.). LexisNexis. p. 304.
  6. .
  7. .
  8. .
  9. .
  10. ^ FDA NEWS RELEASE: FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body, Oct. 14, 2011 https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm275814.htm
  11. ^ a b Jon Thompson; Patricia Baird; Jocelyn Downie, Report of the Committee of Inquiry on the Case Involving Dr. Nancy Olivieri, the Hospital for Sick Children, the University of Toronto, and Apotex Inc. (PDF), www.caut.ca, retrieved 8 December 2015
  12. S2CID 32796175
    .
  13. ^ http://www.aaas.org/aboutaaas/awards/freedom/freedom2009.shtml
  14. ^ Cressey, Daniel. "Scientists honoured for facing down lawsuits to reveal findings". Research Professional News. Retrieved 25 October 2023.

Further reading

External links